In product portfolio acquisition from Medilink A/S. Â
Westerberg & Partners has advised EQL Pharma AB (publ) and its subsidiary EQL Pharma Int AB in the acquisition of a product portfolio of well-established medicinal products consisting of Buronil (melperone), Folimet (folic acid/B-vitamin), Hydromed (hydrochlorothiazide) and Marplan (isocarboxazid) from Danish company Medilink A/S, a subsidiary of Doc-Bibawo A/S, for DKK 120 million.
The completion of the acquisition is subject to (i) a financing condition and (ii) FDI approval by the Danish Business Authority.
The team from Westerberg & Partners consisted of Malcolm Wiberg, Jonas Löfgren, Josefine Arvebratt and Mathilda Wahlgren.
